On April 24, 2024, we entered into an asset purchase agreement with Napp Pharmaceutical Group Limited (Napp), an affiliate of Mundipharma Medical Company, pursuant to which we sold to Napp all of ...

On April 24, 2024, we entered into an asset purchase agreement with Napp Pharmaceutical Group Limited (Napp), an affiliate of Mundipharma Medical Company, pursuant to which we sold to Napp all of ...

BERLIN — Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the ...

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial Severe flu season enables potential mid-year assessment of efficacy Closed $105.0 million financing with new and existing investors ...

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial Severe flu season enables potential mid-year assessment of efficacy Closed $105.0 million financing with new and existing investors ...

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth ...